Results 161 to 170 of about 102,823 (356)

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

open access: yesAllergy, EarlyView.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier   +4 more
wiley   +1 more source

Industrial and intellectual capital clusters in the Baltic states [PDF]

open access: yes
Various recent developments, eg the 'new economic geography' as exemplified by say, Krugman, P. (1991) or work originating in the business literature (Porter 1998), point to industrial and intellectual capital clusters as key factors associated with ...
Basarova, Julija   +2 more
core  

Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments

open access: yesAllergy, EarlyView.
ABSTRACT Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments.
Rafael José Vieira   +230 more
wiley   +1 more source

Tick‐Borne Encephalitis (TBE) Vaccine in the National Immunisation Programme—For Whom, When and Where?

open access: yesActa Paediatrica, EarlyView.
ABSTRACT The incidence of Tick‐borne encephalitis (TBE) cases has increased. The presumed location of transmission of Tick‐borne encephalitis virus (TBEV) has been expanding increasingly in the western parts of Europe during the past decade. There has also been an increased incidence of surveillance‐reported TBE cases in southern Sweden and southern ...
H. H. Askling, D. Zavadska
wiley   +1 more source

Home - About - Disclaimer - Privacy